Protagenic Therapeutics' Peptide PT00114 To Be Highlighted At Boston Summit In Presentation Titled "Novel Blood-Brain Barrier Penetrating Peptide: Opening New Doors in Neuro-Psychiatric Treatment" On April 23, 2024
Protagenic Therapeutics' Peptide PT00114 To Be Highlighted At Boston Summit In Presentation Titled "Novel Blood-Brain Barrier Penetrating Peptide: Opening New Doors in Neuro-Psychiatric Treatment" On April 23, 2024
Chief Operating Officer to Present Key Advances at Peptide Therapeutics Summit
NEW YORK, NY / ACCESSWIRE / April 17, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a pioneer in biopharmaceutical research, announced today that Dr. Andrew Slee, Chief Operating Officer, will present a talk on PT00114, the company's promising new drug candidate, at the Peptide Based Therapeutic Summit in Boston.
Titled "Novel Blood-Brain Barrier Penetrating Peptide: Opening New Doors in Neuro-Psychiatric Treatment," Dr. Slee's talk will focus on the groundbreaking structure of PT00114, designed to efficiently cross the blood-brain barrier and unlock new potential in treating serious neuro-psychiatric conditions. He will share compelling preclinical data and insights into the ongoing clinical safety trial that underline the therapeutic's efficacy and innovative approach.
Event Details:
Topic: Novel Blood-Brain Barrier Penetrating Peptide: Opening New Doors in Neuro-Psychiatric Treatment
Speaker: Dr. Andrew Slee, PhD, COO of Protagenic Therapeutics
Date & Time: 2:00 pm EST, April 23, 2024
Location: Hilton Boston Logan Airport, Boston, MA
Talk Info: Speaker Agenda
About the Peptide Based Therapeutics Summit:
This premier event is planned to gather industry leaders to discuss the latest advancements in peptide therapy, focusing on enhancing drug design, delivery, and therapeutic efficacy across a variety of diseases. This inaugural summit will cover the latest strategies in improving oral bioavailability and targeted cellular delivery, critical in the next generation of peptide therapeutics.
首席運營官將在肽療法峯會上介紹關鍵進展
紐約州紐約/ACCESSWIRE/2024年4月17日/生物製藥研究的先驅Protagenic Therapeutics, Inc.(納斯達克股票代碼:PTIX)今天宣佈,首席運營官安德魯·斯利博士將在波士頓多肽類治療峯會上就該公司有前途的新候選藥物 PT00114 發表演講。
斯利博士的演講標題爲 “新型血腦屏障穿透肽:打開神經精神治療的新大門”,將重點介紹 PT00114 的開創性結構,該結構旨在有效穿越血腦屏障,釋放治療嚴重神經精神疾病的新潛力。他將分享令人信服的臨床前數據和對正在進行的臨床安全性試驗的見解,這些試驗強調了該療法的療效和創新方法。
活動詳情:
題目:新型血腦屏障穿透肽:開啓神經精神治療的新大門
演講者:安德魯·斯利博士,Protagenic Therapeutics首席運營官
日期和時間:美國東部標準時間下午 2:00,2024 年 4 月 23 日
地點:馬薩諸塞州波士頓洛根機場希爾頓酒店
講座信息:演講者議程
關於基於肽的療法峯會:
這項頂級活動計劃匯聚行業領導者,討論肽療法的最新進展,重點是增強各種疾病的藥物設計、交付和治療療效。本次首屆峯會將涵蓋提高口服生物利用度和靶向細胞遞送的最新策略,這對於下一代肽療法至關重要。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧